Mitchell Dowsett
Overview
Explore the profile of Mitchell Dowsett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
6341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tutt A, Tovey H, Chon U Cheang M, Kernaghan S, Kilburn L, Gazinska P, et al.
Nat Med
. 2018 May;
24(5):628-637.
PMID: 29713086
Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused...
12.
Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al.
Science
. 2018 Feb;
359(6378):920-926.
PMID: 29472484
Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs...
13.
Cuzick J, Brentnall A, Dowsett M
Oncotarget
. 2017 Dec;
8(59):99211-99212.
PMID: 29245890
No abstract available.
14.
Howell A, Ashcroft L, Fallowfield L, Eccles D, Eeles R, Ward A, et al.
Cancer Epidemiol Biomarkers Prev
. 2017 Nov;
27(1):58-66.
PMID: 29097444
Ovarian suppression in premenopausal women is known to reduce breast cancer risk. This study aimed to assess uptake and compliance with ovarian suppression using the luteinizing hormone releasing hormone (LHRH)...
15.
Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y
J Natl Cancer Inst
. 2017 Sep;
110(2).
PMID: 28859291
Background: Despite increasing evidence supporting the clinical utility of immune infiltration in the estrogen receptor-negative (ER-) subtype, the prognostic value of immune infiltration for ER+ disease is not well defined....
16.
Loibl S, Turner N, Ro J, Cristofanilli M, Iwata H, Im S, et al.
Oncologist
. 2017 Jun;
22(9):1028-1038.
PMID: 28652278
Background: The efficacy and safety of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, combined with fulvestrant and goserelin was assessed in premenopausal women with advanced breast cancer (ABC) who had progressed...
17.
Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, et al.
Proc Natl Acad Sci U S A
. 2017 May;
114(22):E4482-E4491.
PMID: 28507152
The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very...
18.
Bartlett J, Ahmed I, Regan M, Sestak I, Mallon E, DellOrto P, et al.
Eur J Cancer
. 2017 May;
79:129-138.
PMID: 28494403
Background: A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor...
19.
Ellis M, Suman V, Hoog J, Goncalves R, Sanati S, Creighton C, et al.
J Clin Oncol
. 2017 Jan;
35(10):1061-1069.
PMID: 28045625
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level...
20.
Cuzick J, Brentnall A, Segal C, Byers H, Reuter C, Detre S, et al.
J Clin Oncol
. 2016 Dec;
35(7):743-750.
PMID: 28029312
Purpose At least 94 common single nucleotide polymorphisms (SNPs) are associated with breast cancer. The extent to which an SNP panel can refine risk in women who receive preventive therapy...